Business Context and Reporting Period
This Form 8-K Current Report was filed by Protalix Biotherapeutics, Inc. on December 22, 2009, regarding events occurring on December 17, 2009. The filing discloses the entry into a material definitive employment agreement and the appointment of a new senior executive.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on executive compensation and appointment details.
- Base Salary: $180,000 annually for the new Vice President.
- Equity Grant: Recommended stock option for 160,000 shares of common stock.
- Exercise Price: Not less than the market price on the date of grant.
- Vesting Schedule: 25% after one year; remainder quarterly over four years.
Material Changes
The primary material change is the appointment of Sandra L. Lauterbach as Vice President, Sales and Commercial Affairs, effective December 18, 2009. This represents a strategic addition to the company's commercial leadership team.
Outlook, Risks, and Management Commentary
Management commentary is limited to the terms of the new employment agreement. Key provisions include:
- Discretionary Bonus: The Company may elect to pay an annual bonus based on criteria determined by the Compensation Committee or the Board.
- Benefits: Includes health care insurance, retirement plan contributions, and allowances for car and cell phone expenses.
- Termination: The agreement is terminable by either party with 60 days' written notice, or by the Company for cause without notice.
- Change of Control: Unvested options vest automatically upon a change of control.
Investor Verification Checklist
- Verify the final grant date and exercise price of the 160,000 stock options once approved by the Board.
- Confirm the specific performance criteria for the discretionary bonus component.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the hiring.
- Monitor future filings for the impact of this appointment on the company's sales and commercial strategy.